Administration of aurora kinase inhibitor and chemotherapeutic agents

Abstract

Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an Aurora kinase inhibitor such as 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt in combination with a platin. Also disclosed are medicaments for use in the treatment of cancer.

What is claimed is: 
     
         1 . A method of treating cancer, comprising administering to a patient in need of such treatment a combination of 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof, and a platin, wherein the cancer is breast cancer, small cell lung cancer, or gastric cancer. 
     
     
         2 . The method of  claim 1 , wherein the cancer is small cell lung cancer, or gastric cancer. 
     
     
         3 . The method of  claim 1 , wherein the cancer is small cell lung cancer. 
     
     
         4 . The method of any of  claims 1 - 3 , wherein the platin is cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin or triplatin. 
     
     
         5 . The method of any of  claims 1 - 3 , wherein the platin is cisplatin, or carboplatin. 
     
     
         6 . The method of any of  claims 1 - 3 , wherein the platin is cisplatin. 
     
     
         7 . The method of any of  claims 1 - 6 , wherein 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof is administered twice a day on each of days 1, 2, 3, 8, 9, 10, 15, 16, and 17 of a 28 day schedule. 
     
     
         8 . The method of any of  claims 1 - 7 , wherein 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof is administered from about 15 mg to about 50 mg per dose. 
     
     
         9 . The method of any of  claims 1 - 8 , wherein 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof is administered about 25 mg per dose. 
     
     
         10 . The method of any of  claims 1 - 8 , wherein 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof is administered about 30 mg per dose. 
     
     
         11 . The method of any of  claims 1 - 8 , wherein 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof is administered about 40 mg per dose. 
     
     
         12 . The method of any one of  claims 1 - 11 , wherein the platin is administered on day 1 of a 28 day schedule. 
     
     
         13 . The method of any one of  claims 1 - 11 , wherein the platin is administered on each of days 1, 8 and 15 of a 28 day schedule. 
     
     
         14 . The method of any one of  claims 1 - 13 , wherein the platin is cisplatin. 
     
     
         15 . The method of  claim 14 , wherein the cisplatin is administered from about 75 mg/m 2  to about 100 mg/m 2  per dose. 
     
     
         16 . The method of  claim 14 , wherein the cisplatin is administered from about 50 mg/m 2  to about 70 mg/m 2  per dose. 
     
     
         17 . The method of  claim 14 , wherein the cisplatin is administered from about 25 mg/m 2  to about 50 mg/m 2  per dose.